论文部分内容阅读
目的观察尤瑞克林联合单唾液酸四己糖神经节苷脂治疗急性脑梗死的疗效及安全性。方法将100例脑梗死患者随机分为两组各50例,对照组根据病情给予相应基础药物治疗。观察组在对照组基础上,给予尤瑞克林0.15 PNAU静脉滴注,每日1次,单唾液酸四己糖神经节苷脂100 mg静脉滴注,每日1次,疗程为21天。结果治疗第21天后,观察组的疗效显著优于对照组,差异有统计学意义(P<0.01)。两组患者治疗前的美国国立卫生研究院卒中量表(NIHSS)评分和日常生活能力(BI)评分比较差异无统计学意义(P>0.05);两组患者治疗21天后的NIHSS评分显著低于治疗前(P<0.05或0.01),BI评分均显著高于治疗前(P<0.01);观察组治疗21天后的NIHSS评分和BI评分改善程度均显著优于对照组(P<0.01)。观察组常见的不良反应为低血压,不良反应的发生率为2%(1/50),为尤瑞克林引起,经停药及补液处理后,血压可在短时间内恢复至正常水平。结论尤瑞克林联合单唾液酸四己糖神经节苷脂治疗急性脑梗死疗效肯定,联合用药过程中未见明显不良反应,无配伍禁忌。
Objective To observe the efficacy and safety of uracil combined with monosialotetrahexosyl ganglioside in the treatment of acute cerebral infarction. Methods 100 cases of cerebral infarction were randomly divided into two groups of 50 cases, the control group according to the condition given the corresponding basic drugs. On the basis of the control group, the observation group was given intravenous drip of irrecynin 0.15 PNAU once a day, and monosialotetrahexosyl ganglioside 100 mg intravenously once daily for 21 days. Results After 21 days of treatment, the efficacy of the observation group was significantly better than that of the control group, the difference was statistically significant (P <0.01). There was no significant difference in NIHSS score and daily living ability (BI) score between the two groups before treatment (P> 0.05). NIHSS scores of the two groups were significantly lower than those of the control group Before treatment (P <0.05 or 0.01), BI score was significantly higher than before treatment (P <0.01). NIHSS score and BI score in observation group after 21 days treatment were significantly better than those in control group (P <0.01). The adverse reaction observed in the observation group was hypotension. The incidence of adverse reactions was 2% (1/50), which was caused by uracrine. After withdrawal and rehydration, blood pressure returned to normal within a short period of time. Conclusion The combination of uracil and monosialotetrahexosyl gangliosides in the treatment of acute cerebral infarction is effective. No adverse reactions were observed during combination therapy, and incompatibility was not observed.